Clinics in Malmö and Solna in Sweden have now started treating migraine patients with Chordate Medical Holding AB's (publ) ("Chordate") K.O.S treatment. It is the first time K.O.S. treatment has been used to treat chronic migraines in regular clinical practice.
"The clinics see a great interest and many people seek the treatment spontaneously. Within a few days, our collaborating clinic in Gothenburg will also be able to offer K.O.S. treatment for chronic migraines.
"The work to establish sales in our selected markets in Europe continues, and the fact that we now have patients undergoing the treatment is very satisfactory," says Anders Weilandt, CEO of Chordate.
Chordate received CE marking of the K.O.S method for treatment of chronic migraines in May 2021. The CE marking means that K.O.S meets the clinical efficacy and safety requirements for chronic migraines in the European Medical Devices Directive. This approval allows Chordate to commercialize migraine treatment freely within the EU, and now the first patients have started treatment in Sweden.
This disclosure was submitted for publication, through the contact person below, on August 19th 2021 at 11.50 am CET.
For further information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Telefon: +46 (0) 733 87 42 77
The following documents can be retrieved from beQuoted
the-first-migraine-patients-2021-08-19-eng.pdf
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more athttps://www.chordate.com/en/
